Our voluntary Board of Trustees meets five times per year, with executive staff present.
David Mayhew CBE
“Dementia is one of society’s greatest challenges and one that affects so many of us personally. I am proud to lead this pioneering charity and am determined to do whatever I can to support and enable future breakthroughs that I hope will significantly change the outcomes for future generations.”
David has been Chair of Alzheimer’s Research UK since 2013 and during that time has overseen a huge transformation at the charity, helping to drive forward our ambitious strategy.
David was the former Chairman of J.P. Morgan Cazenove and is now Vice Chairman of J.P. Morgan’s global investment bank. Besides excellence in his field, David also brings a strong personal commitment to driving forward Alzheimer’s Research UK to support new breakthroughs in dementia research. He is currently the Dementia Envoy for the UK – appointed by the Prime Minister in 2016 – which means he is playing a wider role in supporting the delivery of the Government’s 2020 Challenge on Dementia.
“Dementia has touched my family like many others. I am extremely passionate about creating hope for sufferers both current and future.”
Mike has been a Trustee since 2014 and was appointed Deputy Chairman in 2016, bringing a wealth experience from his many years working in the advertising industry.
Mike started out at Saatchi & Saatchi in 1984 and has worked at Omnicom Group for the last 17 years. He became CEO of PHD Worldwide in 2007. Today PHD is one of the world’s fastest growing and most awarded media agencies, with over 3,000 staff working for major global brands like Unilever, Hewlett Packard, GSK, Elizabeth Arden, Bayer, Canon, Porsche, Hyatt, and SAP.
“Research into the causes and prevention of dementias is essential if we are to alleviate or cure these terrible conditions. My background is in finance, and I felt that I could best help Alzheimer’s Research UK with its strategic financial control and with its investment asset allocation. Both are proving to be hugely interesting and rewarding.”
Nick is our Treasurer and was appointed as a Trustee in 2015.
After beginning his career in the oil industry, Nick spent many years in the City of London where he was employed as an equity investment analyst specialising in valuing assets and companies in the oil and gas sector. He now works as a consultant both to the energy and to the investment industries, and as a financial trainer.
Nick chairs the Finance and Investment Sub Committee of the Board and works closely with the Executive Director of Finance and Operations.
“Dementia touches the lives of so many of us, and yet until recently lagged significantly behind many other medical conditions in terms of public understanding and support, so I became a trustee of Alzheimer’s Research UK in the hope that I could play some small part in changing that situation and by so doing help in the search for an end to the devastating impact of dementia.”
Giles joined the Board of Trustees in April 2017.
He is a Partner at Simmons & Simmons, the international commercial law firm, and has been head of the UK Corporate Group since 2012. Giles sits on the Audit and Risk Sub Committee and Legacy Sub Committee of the board, bringing valuable legal expertise.
Dr Rupert Evenett
“Science and research have achieved so much in health that they are formidable creators of hope. I can’t think of a better contribution to human wellbeing than supporting their fight against dementia.”
Dr Rupert Evenett is the chair of ARUK’s Audit and Risk Sub Committee, which has oversight of all areas of financial audit, risk and compliance.
He joined ARUK as a Trustee in 2014 and brings vast experience from investment and finance roles, as well as social enterprise and the voluntary and educational sectors. He plays a key role at ARUK working with different departments, to ensure there is strong oversight of all areas of risk and compliance.
Prof Rob Howard
“Both my grandfather, Jack, and my step-father, Harold, suffered with Alzheimer’s disease and in both cases the experience for our family was protracted, sad and painful. Our failure to translate the astonishing advances that I have seen in Neuroscience during my working lifetime into treatments that can have meaningful impact on the lives of the people with dementia and their families that I work with just shows what a pivotal point we have reached in the fight against Alzheimer’s disease. This is what drives me and my colleagues in our research and is why I wanted to support ARUK in their mission to see life-changing treatments in the next decade.”
Rob is one of our Scientific Trustees and joined ARUK in May 2018.
He brings valuable expertise from his role as Professor of Old Age Psychiatry at University College London and Honorary Consultant Psychiatrist at Camden and Islington NHS Trust. Rob has over 30 years of experience of working clinically with people with dementia and in applied research to find and evaluate better treatments. This insight is an enormous help to our research and policy teams.
Dr Ruth McKernan CBE
“I am joining Alzheimer’s Research UK because we all know someone who has suffered from the disease. I just want to bring what I have to help.”
Ruth is a Scientific Trustee. As a neuroscientist with more than 25 years of research experience in the pharmaceutical industry, she brings valuable expertise to the Board particularly around our drug discovery work.
Her previous roles include Senior Vice President at Pfizer and Head of the Merck Neuroscience Research Centre. She also spent the last three years as CEO of InnovateUK, the Government’s Innovation agency helping to create new businesses and drive economic growth. More recently, she has taken on a Consultancy role with the Dementia Discovery Fund (DDF). She was awarded a CBE in 2013 for services to business, innovation and skills.
Caroline van den Brul MBE
“Many previously deadly diseases are no longer life limiting, or even significantly life-changing. Alzheimer’s disease is not one of them – yet. I want that to change. It is too late for my mother and my husband who both faded and then died with Alzheimer’s but it is not too late for some of those they loved. I am a Trustee of ARUK because of them, and because I believe the only way to make Alzheimer’s a treatable condition is to fund the essential research.”
Caroline joined ARUK in May 2017. She has a wide skill set which is already helping ARUK’s science communications and engagement activity.
Caroline is a narrative-skills coach specialising in helping scientists communicate their ideas and the value of their work to colleagues, the public and funders. She had a distinguished 30-year career with the BBC as a programme maker (credits include Horizon, Tomorrow’s World Hospital Watch and the Ri Christmas Lectures) and as the creativity leader for the implementation of an ambitious culture-change programme.
Caroline became a supporter of the work of ARUK during the time her husband and mother were both living with Alzheimer’s disease. She joined the Board of Trustees in April 2017.
Shirley Cramer CBE
“When my mother was diagnosed with Alzheimer’s Disease, I began to realise that dementia research was way behind other diseases like cancer. I felt there needed to be more of an urgency to prioritise dementia research, which is why I’m passionate about what Alzheimer’s Research UK does. I know there will be solutions in the future, such as new treatments and earlier diagnosis, and I’m really proud to be a part of it.”
Shirley became a Trustee in 2014, after having been Interim Chief Executive of Alzheimer’s Research UK in 2012 for six months.
She sits on our Audit and Risk and HR Remuneration Committee, playing a key role in driving ARUK’s strategy and excellence. She is currently Chief Executive of the Royal Society for Public Health and is an experienced voluntary sector leader in both the UK and the USA. She was previously Chief Executive of Dyslexia Action, the UK’s leading independent provider of services for individuals with dyslexia and other specific learning difficulties for over a decade. She is Chair of the thinktank, British Future.
Christopher became a Trustee of ARUK in 2015 and brings a wealth of expertise from the financial sector. He works closely with ARUK’s major giving team around potential opportunities.
Since 2012 he has been a Senior Advisor to Morgan Stanley and prior to that served in a number of capacities for the company, including Vice Chairman – Institutional Securities, Head of Global Capital Markets and a member of the Firm’s Management Committee. He joined Morgan Stanley in 2006 from CQS, a hedge fund group, where he served as Chairman. He previously spent 19 years at Credit Suisse in a wide range of senior investment banking and executive positions. Christopher is Chaiman of Starcount Pte. and Artorius Wealth Management Limited.